Science In Service.
Informing Ontario’s response to COVID-19
SCIENCE BRIEFS
A collective lens into emerging scientific evidence.
-
Risk of Vaccine-Induced Thrombotic Thrombocytopenia (VITT) following the AstraZeneca/COVISHIELD Adenovirus Vector COVID-19 Vaccines
May 11, 2021
-
Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following Adenovirus Vector COVID-19 Vaccination: Interim Guidance for Healthcare Professionals in the Outpatient Setting
May 10, 2021
-
Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following Adenovirus Vector COVID-19 Vaccination: Interim Guidance for Healthcare Professionals in Emergency Department and Inpatient Settings
May 10, 2021
-
Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following Adenovirus Vector COVID-19 Vaccination: Lay Summary
May 7, 2021
-
Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following Adenovirus Vector COVID-19 Vaccination
May 7, 2021
-
Remdesivir for Hospitalized Patients with COVID-19
May 6, 2021
-
Update on COVID-19 Projections
April 29, 2021
-
Benefits of Paid Sick Leave During the COVID-19 Pandemic
April 28, 2021